Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Paolo Gisondi
- Phone Number: +39 0458122547
- Email: paolo.gisondi@univr.it
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Group 1
Inclusion Criteria:
- Aged 18 to 75 years old
- Individuals with a clinical diagnosis of moderate-to-severe chronic plaque psoriasis confirmed by the Investigator
- Continuous immunosuppressive therapy (etanercept, adalimumab, infliximab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, apremilast, methotrexate, ciclsoporin, acitretin) for the past 3 months
- Is willing and able to sign informed consent to participate
Exclusion Criteria:
- Patients unwilling to undergo noasopharyngeal swab
- Inability to give informed consent
Group 2
Inclusion Criteria:
- Aged 18 to 75 years old
- Partner of a patient with psoriasis enrolled in the study
- Is willing and able to sign informed consent to participate
Exclusion Criteria:
- Personal history of psoriasis
- Ongoing immunosuppressive therapy
- Patients unwilling to undergo noasopharyngeal swab
- Inability to give informed consent
Group 3
- Aged 18 to 75 years old
- Individuals with a clinical diagnosis of moderate-to-severe atopic dermatitis confirmed by the Investigator
- Continuous therapy with dupilumab for the past 3 months
- Is willing and able to sign informed consent to participate
Exclusion Criteria:
- Patients unwilling to undergo noasopharyngeal swab
- Inability to give informed consent
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Group 1
Patients with chronic plaque psoriasis on immunosuppressant therapy
|
Nasopharyngeal swab for the molecular diagnosis of COVID-19 infection
|
|
Group 2
Psoriatic patients' partners
|
Nasopharyngeal swab for the molecular diagnosis of COVID-19 infection
|
|
Group 3
Patients with atopic dermatitis treated with dupilumab
|
Nasopharyngeal swab for the molecular diagnosis of COVID-19 infection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Point prevalence of COVID-19 infection
Time Frame: Baseline up to 6 months
|
Baseline up to 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of COVID-19 infection
Time Frame: Baseline up to 6 months
|
Baseline up to 6 months
|
|
Percentage of subjects presenting fever or respiratory symptoms
Time Frame: Baseline up to 6 months
|
Baseline up to 6 months
|
|
Evaluate the relationship between COVID-19 infection and chronic pharmacological treatments
Time Frame: Baseline up to 6 months
|
Baseline up to 6 months
|
|
Evaluate the relationship between COVID-19 infection and comorbid medical conditions
Time Frame: Baseline up to 6 months
|
Baseline up to 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Skin Diseases
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease Attributes
- Skin Diseases, Papulosquamous
- COVID-19
- Coronavirus Infections
- Infections
- Communicable Diseases
- Psoriasis
Other Study ID Numbers
Other Study ID Numbers
- Gisondi 4
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.